Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics

Clinical and Experimental Immunology

Volumn 165, Issue 3, 2011, Pages 329-337

  Donnou, S ^a,b,c   Galand, C ^a,b,c   Daussy, C ^a,b,c   Crozet, L ^a,b,c   Fridman, W H ^a,b,c   Sautes Fridman C ^a,b,c   Fisson, S ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Immune microenvironment; Intracerebral B cell lymphoma; Intrasplenic B cell lymphoma; Lymphocytes; Privileged site

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNE ADAPTIVE MICROENVIRONMENT PROFILE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL PARAMETERS; INTRACEREBRAL B CELL LYMPHOMA; INTRASPLENIC B CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGEN-PRESENTING CELLS; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOKINES; DENDRITIC CELLS; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, NUDE; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS; TUMOR MICROENVIRONMENT;

EID: 79960972280     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04416.x     Document Type: Article

References (33)

1. Soussain C, Hoang-Xuan K. Primary central nervous system lymphoma: an update. Curr Opin Oncol 2009; 21:550-8.
2. Lin CH, Kuo KT, Chuang SS etal. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006; 12:1152-6.
3. Tun HW, Personett D, Baskerville KA etal. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111:3200-10.
4. Camilleri-Broet S, Criniere E, Broet P etal. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107:190-6.
5. Montesinos-Rongen M, Brunn A, Bentink S etal. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 2008; 22:400-5.
6. Jahnke K, Thiel E. Treatment options for central nervous system lymphomas in immunocompetent patients. Expert Rev Neurother 2009; 9:1497-509.
7. Schultz CJ, Bovi J. Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys 2010; 76:666-78.
8. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007; 28:12-18.
9. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29:58-69.
10. Kaur G, Han SJ, Yang I, Crane C. Microglia and central nervous system immunity. Neurosurg Clin N Am 2010; 21:43-51.
11. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308:1314-18.
12. Aloisi F. Immune function of microglia. Glia 2001; 36:165-79.
13. Badie B, Bartley B, Schartner J. Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas. J Neuroimmunol 2002; 133:39-45.
14. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 2005; 51:279-85.
15. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 2010; 17:6-10.
16. Prins RM, Shu CJ, Radu CG etal. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 2008; 57:1279-89.
17. Proescholdt MA, Merrill MJ, Ikejiri B etal. Site-specific immune response to implanted gliomas. J Neurosurg 2001; 95:1012-19.
18. Touitou V, Daussy C, Bodaghi B etal. Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci 2007; 48:3223-9.
19. Kadoch C, Dinca EB, Voicu R etal. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 2009; 15:1989-97.
20. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001; 166:2717-26.
21. Hatterer E, Touret M, Belin MF, Honnorat J, Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS ONE 2008; 3:e3321.
22. Nataf S, Strazielle N, Hatterer E, Mouchiroud G, Belin MF, Ghersi-Egea JF. Rat choroid plexuses contain myeloid progenitors capable of differentiation toward macrophage or dendritic cell phenotypes. Glia 2006; 54:160-71.
23. Dieu-Nosjean MC, Antoine M, Danel C etal. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-17.
24. Biollaz G, Bernasconi L, Cretton C etal. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol 2009; 39:1323-33.
25. Curti A, Pandolfi S, Valzasina B etal. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007; 109:2871-7.
26. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007; 178:6840-8.
27. Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 2009; 124:239-44.
28. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111:5359-70.
29. Haas J, Schopp L, Storch-Hagenlocher B etal. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis. Blood 2008; 111:761-6.
30. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009; 69:5522-30.
31. Ifergan I, Kebir H, Bernard M etal. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008; 131:785-99.
32. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30:646-55.
33. Zhou L, Lopes JE, Chong MM etal. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236-40.